---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-22-000132"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:46:04.257658+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO

## Summary
- Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).
- Adjusted EBITDA negative $16M vs positive $5M in Q2 2021; adjusted net loss $20M vs $1M.
- Chris Smith appointed CEO effective Aug 15; Vishal Sikri named President, Pharma Services in May.
- Cash and securities $466M; company launched enterprise-wide performance improvement plan.

## SEC filing metadata
- accession: 0001077183-22-000132
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/0001077183-22-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/neo-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-22-000132
- JSON: https://secwatch.observer/filing/0001077183-22-000132.json
- Plain text: https://secwatch.observer/filing/0001077183-22-000132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.